OBJECTIVE: The present study was designed to investigate the role of X-ray cross-complementing group 1 (XRCC1) and apurinic/apyrimidinic endonuclease 1 (APE1) polymorphisms in apoptosis and the risk of ulcerative colitis (UC). MATERIALS AND METHODS: Blood samples from 384 unrelated subject (age range 18-65 years; 171 with UC, 213 healthy controls) were collected after colonoscopy. Genomic DNA was isolated and genotyped for XRCC1 Arg399Gln and APE1 Asp148Glu using a confronting two-pair primers polymerase chain reaction. Apoptosis and intracellular reactive oxygen species (ROS) levels in peripheral blood mononuclear cells were measured using annexin-V and H(2)DCFDA assay, respectively. RESULTS: The frequency of genotype Arg399Gln (heterozygous) of XRCC1 gene was significantly higher in patients with UC than the controls (odds ratio [OR] 1.73; 95% confidence interval [CI] 1.13-2.64; p = 0.01). Similarly the genotypic frequency of APE1 Asp148Glu showed statistically significant incidence among UC subjects (OR 1.54; 95% CI 1.02-2.33; p = 0.04). Polymorphism in XRCC1 Arg399Gln and APE1 Asp148Glu together considerably increased the risk of UC (OR 2.303; 95% CI 1.43-3.69; p = 0.0007). ROS levels were high in UC subjects compared with controls (p = 0.01). CONCLUSION: Polymorphisms in XRCC1 Arg399Gln and APE1 Asp148Glu significantly increased the rate of apoptosis and risk of ulcerative colitis.
OBJECTIVE: The present study was designed to investigate the role of X-ray cross-complementing group 1 (XRCC1) and apurinic/apyrimidinic endonuclease 1 (APE1) polymorphisms in apoptosis and the risk of ulcerative colitis (UC). MATERIALS AND METHODS: Blood samples from 384 unrelated subject (age range 18-65 years; 171 with UC, 213 healthy controls) were collected after colonoscopy. Genomic DNA was isolated and genotyped for XRCC1 Arg399Gln and APE1 Asp148Glu using a confronting two-pair primers polymerase chain reaction. Apoptosis and intracellular reactive oxygen species (ROS) levels in peripheral blood mononuclear cells were measured using annexin-V and H(2)DCFDA assay, respectively. RESULTS: The frequency of genotype Arg399Gln (heterozygous) of XRCC1 gene was significantly higher in patients with UC than the controls (odds ratio [OR] 1.73; 95% confidence interval [CI] 1.13-2.64; p = 0.01). Similarly the genotypic frequency of APE1 Asp148Glu showed statistically significant incidence among UC subjects (OR 1.54; 95% CI 1.02-2.33; p = 0.04). Polymorphism in XRCC1 Arg399Gln and APE1 Asp148Glu together considerably increased the risk of UC (OR 2.303; 95% CI 1.43-3.69; p = 0.0007). ROS levels were high in UC subjects compared with controls (p = 0.01). CONCLUSION: Polymorphisms in XRCC1 Arg399Gln and APE1 Asp148Glu significantly increased the rate of apoptosis and risk of ulcerative colitis.
Authors: Mariana C Stern; Kimberly D Siegmund; Román Corral; Robert W Haile Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Sonja I Berndt; Wen-Yi Huang; M Daniele Fallin; Kathy J Helzlsouer; Elizabeth A Platz; Joel L Weissfeld; Timothy R Church; Robert Welch; Stephen J Chanock; Richard B Hayes Journal: Cancer Res Date: 2007-02-01 Impact factor: 12.701
Authors: Rachel A Caston; Silpa Gampala; Lee Armstrong; Richard A Messmann; Melissa L Fishel; Mark R Kelley Journal: Drug Discov Today Date: 2020-10-24 Impact factor: 7.851
Authors: Jae Sung Park; Hye Lim Kim; Yeo Jin Kim; Jong-Il Weon; Mi-Kyung Sung; Hai Won Chung; Young Rok Seo Journal: Oxid Med Cell Longev Date: 2014-08-26 Impact factor: 6.543
Authors: S P Sujitha; D Thirumal Kumar; C George Priya Doss; K Aavula; R Ramesh; S Lakshmanan; S Gunasekaran; G Anilkumar Journal: PLoS One Date: 2016-01-29 Impact factor: 3.240